Thrombopoietin emerges as a new haematopoietic cytokine that confers cardioprotection against acute myocardial infarction

Cardiovascular Research

Volumn 77, Issue 1, 2008, Pages 2-3

  Calvert, John W ^a   Lefer, David J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOXORUBICIN; ERYTHROPOIETIN; HEMOPOIETIC GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE 2; RECOMBINANT THROMBOPOIETIN; STAT3 PROTEIN; THROMBOPOIETIN;

ACUTE HEART INFARCTION; APOPTOSIS; CARDIOTOXICITY; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONVALESCENCE; DOSE RESPONSE; EDITORIAL; ENZYME ACTIVATION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; THROMBOCYTOPOIESIS;

ACUTE DISEASE; ANIMALS; HUMANS; JANUS KINASE 2; MYOCARDIAL INFARCTION; STAT3 TRANSCRIPTION FACTOR; THROMBOPOIETIN;

EID: 38849093309     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm064     Document Type: Editorial

References (15)

1. Bath PMW, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev 2007;CD005207. doi:10.1002/14651858. CD005207.pub3.
2. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005;19:243-250.
3. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005;11:305-311.
4. Baker JE, Su J, Hsu A, Shi Y, Zhao M, Strande JL et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res 2008;77:44-53.
5. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-3347.
6. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469.
7. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211-2220.
8. Baker JE. Erythropoietin mimics ischaemic preconditioning. Vascul Pharmacol 2005;42:233-241.
9. Takeishi Y, Huang Q, Wang T, Glassman M, Yoshizumi M, Baines CP et al. Src family kinase and adenosine differentially regulate multiple MAP kinases in ischaemic myocardium: modulation of MAP kinases activation by ischaemic preconditioning. J Mol Cell Cardiol 2001;33:1989-2005.
10. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2000;97:315-319.
11. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischaemic injury. Circ Res 2004;95:187-195.
12. Barry SP, Townsend PA, Latchman DS, Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med 2007;13:82-89.
13. Tanno M, Miura T, Tsuchida A, Miki T, Nishino Y, Ohnuma Y et al. Contribution of both the sarcolemmal K(ATP) and mitochondrial K(ATP) channels to infarct size limitation by K(ATP) channel openers: differences from preconditioning in the role of sarcolemmal K(ATP) channels. Naunyn Schmiedebergs Arch Pharmacol 2001;364:226-232.
14. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res 1999;84:973-979.
15. Calvert JW, Lefer DJ. Statin therapy and myocardial no-reflow. Br J Pharmacol 2006;149:229-231.